Compare IONQ Inc (IONQ) vs Revvity Inc (RVTY) Price & Performance

IONQ trades at $39.45, down 4.57% today, showing bearish technical signals with mixed fundamental performance. The company reported strong revenue growth ($130M in 2025, projected $246M in 2026) but significant losses (-$510M net income in 2025). Recent earnings show a pattern of beats and misses, with Q2 2026 missing expectations. Technical indicators show bearish momentum despite some oversold conditions, with key support at $36 and resistance at $41.

Outlook remains speculative with high growth potential but substantial execution risks. Analyst consensus is split with a $62.75 price target suggesting 59% upside, though profitability challenges and cash burn (-$283M operating cash flow in 2025) present significant hurdles. The quantum computing market opportunity is substantial, but IONQ must demonstrate path to profitability to justify current valuations.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.